



PDL BioPharma, Inc.
Investor Relations Department
932 Southwood Blvd.
Incline Village, NV 89451
United States

Visit IR website [↗](#)
Sign-up for email alerts [↗](#)

NASDAQ: PDLI ¹

| | |
|----------------------|----------------------------|
| Last Trade: | 2.35 |
| Trade Time: | 4:00 PM ET May 22, 2017 |
| Change: | 0.00 (0.000%) |
| Day Range | N/A - N/A |
| 52-Week Range | 1.93 - 3.77 |
| Volume | N/A |
| Market Cap. (\$M) | 378.303 |
| Shares Out (M) | 160.980 |

¹ The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

Company Profile

PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. Today, PDL is focused on intellectual property asset management, investing in new royalty bearing assets and maximizing the value of its patent portfolio and related assets. ... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- May 11, 2017*
[LENSAR® And PDL BioPharma Complete Strategic Financial Restructuring Of LENSAR](#)
- May 3, 2017*
[PDL BioPharma Announces First Quarter 2017 Financial Results](#)
- Apr 26, 2017*
[PDL BioPharma to Announce First Quarter 2017 Financial Results on May 3, 2017](#)
- Apr 24, 2017*
[PDL BioPharma Announces Settlement of Keytruda Patent Infringement Lawsuit with Merck](#)
- Apr 6, 2017*
[PDL BioPharma to Hold Annual Meeting of Stockholders on June 9, 2017](#)

Events [\[View all \]](#)

- Jun 9, 2017 10:00 AM PT*
[Annual Meeting of Stockholders](#)
- Financials [\[View all \]](#)*
[First Quarter Financial Results](#)
- Mar 1, 2017*
[Annual Report \(10-K\)](#)
- Apr 28, 2017*
[Definitive Proxy Statement](#)
- May 3, 2017*
[Quarterly Report \(10-Q\)](#)
- Nov 3, 2016*
[Quarterly Report \(10-Q\)](#)
- Aug 4, 2016*
[Quarterly Report \(10-Q\)](#)